The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
19 08 2021
19 08 2021
Historique:
received:
15
02
2021
accepted:
26
07
2021
entrez:
20
8
2021
pubmed:
21
8
2021
medline:
18
9
2021
Statut:
epublish
Résumé
Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of candidate therapies. The PDX collection comprises 59 tumors collected from 30 patients between 2012-2020, coinciding with availability of abiraterone and enzalutamide. The PDXs represent the clinico-pathological and genomic spectrum of prostate cancer, from treatment-naïve primary tumors to castration-resistant metastases. Inter- and intra-tumor heterogeneity in adenocarcinoma and neuroendocrine phenotypes is evident from bulk and single-cell RNA sequencing data. Organoids can be cultured from PDXs, providing further capabilities for preclinical studies. Using a 1 x 1 x 1 design, we rapidly identify tumors with exceptional responses to combination treatments. To govern the distribution of PDXs, we formed the Melbourne Urological Research Alliance (MURAL). This PDX collection is a substantial resource, expanding the capacity to test and prioritize effective treatments for prospective clinical trials in prostate cancer.
Identifiants
pubmed: 34413304
doi: 10.1038/s41467-021-25175-5
pii: 10.1038/s41467-021-25175-5
pmc: PMC8376965
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
5049Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s).
Références
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
BMC Med Genomics. 2021 Jan 29;14(1):34
pubmed: 33514375
Clin Cancer Res. 2013 Sep 15;19(18):5003-15
pubmed: 23881923
J Clin Invest. 2019 Jul 30;129(10):4492-4505
pubmed: 31361600
Nat Med. 2015 Nov;21(11):1318-25
pubmed: 26479923
Nat Rev Cancer. 2017 Apr;17(4):254-268
pubmed: 28104906
Nat Commun. 2020 Apr 20;11(1):1884
pubmed: 32313004
Cell. 2014 Sep 25;159(1):176-187
pubmed: 25201530
Cancer Res. 2013 Aug 1;73(15):4885-97
pubmed: 23737486
N Engl J Med. 2019 Jul 11;381(2):121-131
pubmed: 31157964
Mol Oncol. 2018 Sep;12(9):1608-1622
pubmed: 30117261
Clin Cancer Res. 2018 Sep 1;24(17):4332-4345
pubmed: 29748182
Sci Transl Med. 2013 May 29;5(187):187ra71
pubmed: 23720582
Prostate. 2013 Sep;73(12):1316-25
pubmed: 23775398
Gigascience. 2018 Jul 1;7(7):
pubmed: 30010766
Cancer Res. 2014 Feb 15;74(4):1272-83
pubmed: 24356420
Cells. 2020 Jun 04;9(6):
pubmed: 32512818
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Nucleic Acids Res. 2019 Jan 8;47(D1):D900-D908
pubmed: 30329142
J Clin Invest. 2008 Aug;118(8):2697-710
pubmed: 18618013
PLoS One. 2017 Dec 20;12(12):e0188709
pubmed: 29261690
Cancer Res. 1996 Jul 1;56(13):3042-6
pubmed: 8674060
Clin Cancer Res. 2020 Sep 15;26(18):4933-4946
pubmed: 32576626
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
Genome Biol. 2019 Mar 27;20(1):65
pubmed: 30917859
PLoS One. 2017 Nov 16;12(11):e0188228
pubmed: 29145505
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Nat Protoc. 2013 May;8(5):836-48
pubmed: 23558784
Nat Commun. 2018 Jun 19;9(1):2404
pubmed: 29921838
BJU Int. 2018 Jun;121(6):971-978
pubmed: 28977728
Mol Oncol. 2014 May;8(3):656-68
pubmed: 24560445
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Oncotarget. 2016 Sep 13;7(37):60475-60490
pubmed: 27528024
Bioinformatics. 2012 Jul 15;28(14):1838-44
pubmed: 22569178
Cancers (Basel). 2019 Mar 12;11(3):
pubmed: 30871108
Prostate. 2015 May;75(6):585-92
pubmed: 25585936
Lancet Oncol. 2018 Jul;19(7):975-986
pubmed: 29880291
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Protoc. 2016 Feb;11(2):347-58
pubmed: 26797458
Am J Pathol. 1996 Sep;149(3):1055-62
pubmed: 8780407
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Am J Pathol. 2012 Feb;180(2):599-607
pubmed: 22189618
Clin Cancer Res. 2012 Feb 1;18(3):666-77
pubmed: 22156612
Clin Cancer Res. 2012 May 1;18(9):2515-25
pubmed: 22392911
Eur Urol. 2020 Oct;78(4):486-488
pubmed: 32636098
J Pathol. 2021 Jun;254(2):121-134
pubmed: 33620092
Eur Urol. 2018 Nov;74(5):562-572
pubmed: 30049486
Clin Cancer Res. 2020 Jun 1;26(11):2487-2496
pubmed: 32086346
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
JCI Insight. 2021 Apr 22;6(8):
pubmed: 33724955
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Eur Urol. 2018 Jun;73(6):949-960
pubmed: 29544736
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Eur Urol. 2006 Feb;49(2):245-57
pubmed: 16413664
Lancet Oncol. 2020 Jan;21(1):162-174
pubmed: 31806540
Nat Biotechnol. 2016 Oct;34(10):1010-1014
pubmed: 27617737
Prostate. 2018 Dec;78(16):1262-1282
pubmed: 30073676
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cancer Discov. 2017 May;7(5):462-477
pubmed: 28331002
Oncogene. 2020 Nov;39(45):6935-6949
pubmed: 32989253
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Nat Commun. 2021 Feb 18;12(1):1117
pubmed: 33602919
Prostate. 2019 Aug;79(11):1326-1337
pubmed: 31212368
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
Sci Rep. 2019 Nov 19;9(1):17052
pubmed: 31745186
J Endocr Soc. 2020 Sep 12;4(11):bvaa132
pubmed: 33094211
Prostate. 2015 Sep;75(13):1475-83
pubmed: 26177841
Cancer Res. 2020 Jun 1;80(11):2286-2297
pubmed: 32152150
Prostate. 2017 May;77(6):654-671
pubmed: 28156002
Cancer Res. 1999 Oct 1;59(19):5030-6
pubmed: 10519419